Akèy › Kansè (tout kalite) › Oklahoma
Etid klinik pou Kansè (tout kalite) nan Oklahoma
15 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Oct 1, 2026 · NCT07024784Registry Study for Radiation Therapy Outcomes
- Oklahoma Proton Center, Oklahoma City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 29, 2026 · NCT01255748Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Prospective Study to Assess a Diagnostic Aid for Cancer
- Hightower Clinical, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 45 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07046260Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Sep 18, 2026 · NCT03435796A Phase 1/1b Study of IAM1363 in HER2 Cancers
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Project: Every Child for Younger Patients With Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07327489GEMINI-NSCLC: NSCLC Biomarker Study
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT05236114Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Oklahoma University Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Nov 13, 2025 · NCT05997017SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT05107674Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2025 · NCT05234177Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- OUHSC Stephenson Cancer Center, Oklahoma City
- Mercy Health Center - Oncology Hematology, Oklahoma City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Nov 27, 2024 · NCT03860883Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.